Conn. Gen. Stat. § 17b-278o: Medicaid coverage for sickle cell disease gene therapies.

(a) The Commissioner of Social Services shall provide Medicaid coverage for gene therapies approved by the federal Food and Drug Administration to treat sickle cell disease.

(b) The commissioner shall apply for any federal initiative to increase cost-effective access to the therapies, including, but not limited to, the Cell and Gene Therapy Access Model administered by the Centers for Medicare and Medicaid Services.

(c) Not later than January 1, 2026, the commissioner shall file a report, in accordance with the provisions of section 11-4a, with the joint standing committee of the General Assembly having cognizance of matters relating to human services on the (1) efforts to increase cost-effective access to the therapies, (2) number of Medicaid recipients who have received Medicaid coverage for the therapies, (3) cost to the state to provide such therapies, and (4) estimated state appropriations needed to provide such coverage.